Jacobs Levy Equity Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-121,559
| Closed | -$453K | – | 1068 |
|
|
2024
Q3 | $453K | Buy |
+121,559
| New | +$453K | ﹤0.01% | 842 |
|
|
2024
Q2 | – | Sell |
-10,215
| Closed | -$53.5K | – | 1073 |
|
|
2024
Q1 | $53.5K | Sell |
10,215
-5,353
| -34% | -$28.1K | ﹤0.01% | 924 |
|
|
2023
Q4 | $81.4K | Buy |
15,568
+3,982
| +34% | +$20.8K | ﹤0.01% | 960 |
|
|
2023
Q3 | $183K | Buy |
+11,586
| New | +$183K | ﹤0.01% | 927 |
|
|
2023
Q1 | – | Sell |
-10,531
| Closed | -$308K | – | 1078 |
|
|
2022
Q4 | $308K | Sell |
10,531
-21,846
| -67% | -$639K | ﹤0.01% | 861 |
|
|
2022
Q3 | $855K | Buy |
32,377
+4,584
| +16% | +$121K | 0.01% | 739 |
|
|
2022
Q2 | $1.24M | Sell |
27,793
-69,097
| -71% | -$3.07M | 0.01% | 709 |
|
|
2022
Q1 | $4.8M | Sell |
96,890
-45,802
| -32% | -$2.27M | 0.03% | 438 |
|
|
2021
Q4 | $7.27M | Sell |
142,692
-20,407
| -13% | -$1.04M | 0.05% | 360 |
|
|
2021
Q3 | $9.1M | Sell |
163,099
-8,741
| -5% | -$488K | 0.06% | 318 |
|
|
2021
Q2 | $7.36M | Buy |
171,840
+13,835
| +9% | +$592K | 0.05% | 360 |
|
|
2021
Q1 | $6.6M | Buy |
158,005
+2,935
| +2% | +$123K | 0.05% | 376 |
|
|
2020
Q4 | $7.22M | Buy |
155,070
+20,994
| +16% | +$978K | 0.06% | 326 |
|
|
2020
Q3 | $5.7M | Buy |
134,076
+40,446
| +43% | +$1.72M | 0.06% | 310 |
|
|
2020
Q2 | $4.49M | Buy |
93,630
+30,389
| +48% | +$1.46M | 0.05% | 363 |
|
|
2020
Q1 | $2.91M | Buy |
63,241
+42,381
| +203% | +$1.95M | 0.04% | 408 |
|
|
2019
Q4 | $1.25M | Buy |
20,860
+4,024
| +24% | +$242K | 0.01% | 643 |
|
|
2019
Q3 | $952K | Buy |
16,836
+590
| +4% | +$33.4K | 0.01% | 620 |
|
|
2019
Q2 | $905K | Buy |
+16,246
| New | +$905K | 0.01% | 658 |
|